|
To detemine whether the bone resorption rate is evaluated by deoxypyridinoline (Dpd) and calcium/creatinine in urine, the bone formation rate is evaluated by osteocalcine in serum and also to evaluate the clinical utility of Dpd, osteocalcin, calcium/creatinine to monitor the hormone replacement therapy effect in postmenopausal women, we divided the patients into three groups, the control group was the women who were premenopausal health state, and the experimental groups were the postmenopausal hormon replacement therapy group and the postmenopausal nontherapy group. Urinary Dpd, serum FSH, ostecalcin, and urinary calcium/creatinine were measured in all groups. The urinary Dpd was significantly decreased in postmenopausal HRT group in comparision to post menopausal HRT nontherapy group (5.16+/-1.93 vs 8.39+/-2.75 p mol/mu mol creatinine). The serum osteocalcin was significantly decreased in postmenopaual HRT group in comparisison to postmenopausal nontherapy group(14.41+/-5.02vs 16.68+/-6.12ng/ml). The urimary ca/cr was significantly decreased in postmenopausal HRT group in comparision to postmenopausal nontherapy group(0.26+/-0.21 vs 0.63+/-0.24 m mol/mol). These markers were good correlated significantly in all groups. It is concluded that the assay of urinary Dpd, calcium/creatine, and serum osteocalcin are useful for the metabolism marker of postmenopausal osteoporosis and it should be useful for the monitoring the effect of hormone replacement therapy in postmenopausal women.
|